These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 22836491)

  • 21. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
    Louzada ML; Carrier M; Lazo-Langner A; Dao V; Kovacs MJ; Ramsay TO; Rodger MA; Zhang J; Lee AY; Meyer G; Wells PS
    Circulation; 2012 Jul; 126(4):448-54. PubMed ID: 22679142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New paradigms in venous thromboprophylaxis of medically ill patients.
    Spyropoulos AC; Raskob GE
    Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venous thromboembolism in cancer patients: expanding horizons.
    Bergqvist D
    Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():19-23. PubMed ID: 12232819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    Agnelli G; George DJ; Kakkar AK; Fisher W; Lassen MR; Mismetti P; Mouret P; Chaudhari U; Lawson F; Turpie AG;
    N Engl J Med; 2012 Feb; 366(7):601-9. PubMed ID: 22335737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
    Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
    Amin AN; Girard F; Samama MM
    Thromb Haemost; 2010 Nov; 104(5):955-61. PubMed ID: 20838741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying cancer patients at risk for venous thromboembolism.
    Sousou T; Khorana A
    Hamostaseologie; 2009 Jan; 29(1):121-4. PubMed ID: 19151861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thromboprophylaxis during chemotherapy in patients with advanced cancer.
    Agnelli G; Verso M
    Thromb Res; 2010 Apr; 125 Suppl 2():S17-20. PubMed ID: 20433999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venous thromboembolism following primary total hip arthroplasty.
    Hitos K; Fletcher JP
    Int Angiol; 2009 Jun; 28(3):215-21. PubMed ID: 19506541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thromboprophylaxis during chemotherapy after advanced cancer.
    Agnelli G; Verso M
    Thromb Res; 2007; 120 Suppl 2():S128-32. PubMed ID: 18023706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population.
    Crowley MP; Eustace JA; O'Shea SI; Gilligan OM
    Clin Appl Thromb Hemost; 2014 Sep; 20(6):600-6. PubMed ID: 24486624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.
    Bergmann JF; Cohen AT; Tapson VF; Goldhaber SZ; Kakkar AK; Deslandes B; Huang W; Anderson FA;
    Thromb Haemost; 2010 Apr; 103(4):736-48. PubMed ID: 20135072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboprophylaxis in ambulatory lung cancer treatment.
    Cavaliere L
    Clin J Oncol Nurs; 2013 Feb; 17(1):74-9. PubMed ID: 23372099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of immobility and importance of risk assessment management for medically ill patients.
    Hull RD
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):268-76. PubMed ID: 22826444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
    Khorana AA; Dalal M; Lin J; Connolly GC
    Cancer; 2013 Feb; 119(3):648-55. PubMed ID: 22893596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
    Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
    Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
    Merli GJ
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S27-34. PubMed ID: 19530157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study.
    Haas SK; Hach-Wunderle V; Mader FH; Ruster K; Paar WD
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):7-13. PubMed ID: 17164492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prophylaxis of VTE in cancer outpatients.
    Imberti D; Benedetti R
    Thromb Res; 2016 Apr; 140 Suppl 1():S103-8. PubMed ID: 27067962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.